---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-042962"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:29:38.813084+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incannex completes Phase 2 dosing of IHL-42X for OSA; topline data expected July 2025

## Summary
- Completed patient dosing in Phase 2 portion of RePOSA study on May 8, 2025; end-of-study follow-up by May 17, 2025.
- Topline results from Phase 2 expected in July 2025; end-of-Phase 2 FDA meeting to follow.
- Phase 3 plan: 440 patients exclusively at U.S. sites; decision supported by site and patient enthusiasm.
- Incannex engaged in preliminary commercial discussions for IHL-42X ahead of data readout.

## SEC filing metadata
- accession: 0001213900-25-042962
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025042962/0001213900-25-042962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025042962/ea0242110-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-042962
- JSON: https://secwatch.observer/filing/0001213900-25-042962.json
- Plain text: https://secwatch.observer/filing/0001213900-25-042962.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.